Proxofim

Proxofim is sold as a senolytic peptide, an improved relative of FOXO4-DRI, aimed at clearing senescent cells and restoring tissue renewal. The single most important thing to say about it is that a search of the peer-reviewed literature returns nothing under that name. There is no paper describing its synthesis, no published sequence, no characterisation data, no animal study, no toxicology, no clinical trial. Everything a buyer is told about Proxofim is either supplied by the vendor selling it or imported wholesale from research done on a different molecule.

That different molecule is FOXO4-DRI, and the research behind it is real. In 2017, Peter de Keizer and colleagues published in Cell a retro-inverso D-amino acid peptide designed to disrupt the interaction between FOXO4 and p53 [1]. Senescent cells survive in part because FOXO4 sequesters p53 in the nucleus, preventing it from triggering apoptosis. Break that interaction, p53 relocates to the mitochondria, and the senescent cell dies while normal cells are spared. In mice, the peptide reduced markers of senescence, restored fitness and fur density in aged animals, and mitigated chemotoxicity. It was one of the more striking results in the senolytics field.

Subsequent work has refined the picture. A 2021 study in Frontiers in Bioengineering and Biotechnology showed FOXO4-DRI selectively removing senescent cells from in vitro expanded human chondrocytes, which is relevant to cartilage repair [2]. A 2025 Nature Communications paper resolved the structural question, identifying the disordered p53 transactivation domain as the actual binding target [3]. A 2026 review in Naunyn-Schmiedeberg's Archives of Pharmacology assessed retro-inverso peptide senolytics as a pharmacological strategy more broadly [4]. This is a legitimate and active research area.

None of it validates Proxofim. A peptide's behaviour depends entirely on its exact sequence, its stereochemistry, and its modifications. FOXO4-DRI's whole design rests on the retro-inverso configuration, which uses D-amino acids in reversed sequence to resist protease degradation while preserving the binding surface. A vendor product described only as FOXO4-related, with no published sequence, could be a close analogue, a truncated fragment, an L-amino acid version with entirely different stability, or something else again. Without independent analytical characterisation there is no way for a buyer to know which. This is not a hypothetical concern in a market where third-party testing has repeatedly found grey-market peptides to be mislabelled or underdosed.

The mechanistic risk also deserves more attention than senolytics marketing usually gives it. Killing senescent cells is not automatically good. Senescent cells accumulate in tissue for reasons, including wound healing, tumour suppression and tissue remodelling, and their removal has context-dependent consequences. A 2023 study in Circulation makes the point sharply: eliminating senescent cells promoted the development and progression of pulmonary hypertension in the model studied [5]. That is a direct demonstration that a broadly applied senolytic can make a disease worse. Senescent cells also accumulate in liver, kidney, vasculature and joint tissue, so a systemically administered apoptosis trigger acts everywhere at once, potentially producing an inflammatory burst from the debris of many dying cells simultaneously.

Layer on top of this the absence of any human data. There is no phase I study of FOXO4-DRI, let alone of Proxofim. There is no human pharmacokinetic profile, no dosing rationale, no tolerability information, and no monitoring protocol that could catch a problem early. The dose figures that circulate online for these peptides vary by orders of magnitude between sources, which is itself evidence that nobody knows.

It is worth noting where the credible clinical senolytic work actually sits. The trials that have reached humans use small molecules, principally dasatinib combined with quercetin, and to a lesser extent fisetin, in small studies with mixed and preliminary results. Peptide senolytics have not entered that stage. Anyone who wants exposure to the senolytics hypothesis with the least unverifiable risk is looking at the small-molecule literature, not at an unpublished peptide.

Our position: Proxofim is tier 5, the lowest rating we assign, and it earns that rating for a specific and unusual reason. Most tier 5 compounds have weak evidence. Proxofim has no evidence of its own at all, and is marketed on the strength of research conducted on a molecule it may or may not resemble. Until a sequence is published and independently characterised, treating Proxofim as a senolytic is an act of faith in a vendor rather than a decision informed by science.